Group 1: Marketing Strategy and Goals - The company is reforming its marketing system to enhance efficiency and effectiveness, aiming for a significant impact on Q2 performance [2][3] - The marketing reform includes structural adjustments, team building, product and market strategies, brand promotion training, and employee assessment incentives [2][3] - The goal is to increase the revenue share from OTC channels and enhance the company's brand value in women's health management [3] Group 2: Research and Development Initiatives - The company focuses on clinical value in R&D, particularly in gynecology, aligning new product pipelines with existing market resources [3][4] - A comprehensive R&D system has been established, covering the entire process from drug discovery to post-market evaluation [3][4] - There is a commitment to significantly increase R&D expenditure and expand the R&D team to enhance capabilities and efficiency [3][4] Group 3: Financial Performance and Market Positioning - The company aims to create 2-3 major products exceeding 500 million CNY in revenue within the next 3-5 years, alongside multiple products generating over 100 million CNY [4] - The strategy includes expanding coverage in essential drug markets and leveraging leading products to drive market growth [4] - The company anticipates a more stable revenue structure from its main products, supported by a solid foundation from secondary products [4] Group 4: Future Growth and Strategic Investments - The company is preparing for the national market launch of traditional Chinese medicine formula granules, focusing on technological advancement and market strength [5] - Investment in Huylun Pharmaceutical is expected to yield significant positive impacts and enhance the company's strategic positioning in the small molecule drug sector [5] - The company plans to implement a new round of equity incentive plans based on performance targets and growth expectations [5]

证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | --- | |------------|-------------------|-------------------|-----------|----------|-------------------| | | | | | 编号： | 2023-006 | | | | | | | | | 投资者关系 | | | | | | | 活动类别 | □新闻发布会 | | □路演活动 | | | | | □现场参观 | | | | | | | | | | | | | | | | | | | | | | | | 诺德基金 | 西部利得基金 | | | | | | | | | | 泰康保险 | | | | | | | | | | 汇添富 | 景顺基金 | | 参与单位名 | | | | | 涌津投资 | | 称及人员姓 | 金百镕投资 | | | | | | 名 | | | | | 高毅资管 | | | | | | | 华宝 ...

Financial Performance - The company's revenue for Q1 2023 was ¥208,755,879.11, a decrease of 16.24% compared to ¥249,216,213.05 in the same period last year[4] - Net profit attributable to shareholders was ¥25,092,336.81, down 18.74% from ¥30,879,340.57 year-on-year[4] - Basic earnings per share decreased to ¥0.1082, down 18.89% from ¥0.1334 in the same period last year[4] - Total operating revenue for Q1 2023 was CNY 208,755,879.11, a decrease of 16.3% compared to CNY 249,216,213.05 in Q1 2022[15] - Net profit for Q1 2023 was CNY 25,092,336.81, down 18.7% from CNY 30,879,340.57 in the same period last year[16] - Basic earnings per share decreased to CNY 0.1082 from CNY 0.1334, reflecting a decline of 18.5%[17] Cash Flow - The net cash flow from operating activities was -¥311,487.89, a decline of 108.43% compared to ¥3,695,741.81 in the previous year[4] - Cash flow from operating activities showed a net outflow of CNY 311,487.89, compared to a net inflow of CNY 3,695,741.81 in Q1 2022[17] - The net cash flow from financing activities increased by 36.75% to ¥50,602,908.34, primarily due to increased bank borrowings[7] - The net cash flow from financing activities was 50,602,908.34 CNY, compared to 37,005,120.20 CNY in the previous year[18] - The net cash flow from investment activities was -34,345,766.82 CNY, compared to a net cash flow of 31,179,154.70 CNY in the previous year[18] - The net increase in cash and cash equivalents was 15,945,653.63 CNY, down from 71,880,016.71 CNY year-over-year[18] - The ending balance of cash and cash equivalents was 116,613,200.61 CNY, compared to 144,358,114.14 CNY at the end of the previous year[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,902,558,635.90, an increase of 3.18% from ¥1,843,850,779.14 at the end of the previous year[4] - Total assets amounted to ¥1,902,558,635.90, up from ¥1,843,850,779.14, indicating an increase of about 3.2%[13] - Total liabilities increased to ¥747,021,674.97 from ¥714,648,981.41, a rise of approximately 4.5%[13] - The company reported a total of ¥1,263,779,120.13 in non-current assets, an increase from ¥1,229,856,973.52, reflecting a growth of approximately 2.7%[13] - The company’s total equity is reported at ¥1,155,536,960.93, showing a slight increase from the previous period[13] Shareholder Information - Total number of common shareholders at the end of the reporting period is 25,325[9] - The company has a total of 80,187,166 shares held by the largest shareholder, accounting for 34.57% of total shares[9] Expenses and Costs - Total operating costs decreased by 14.6% to CNY 183,519,448.53 from CNY 214,995,242.32 year-over-year[15] - The company reported a decrease in sales expenses to CNY 100,210,367.91 from CNY 121,925,070.24, reflecting cost management efforts[15] - Research and development expenses increased to CNY 3,990,027.82, up from CNY 3,589,480.60, indicating a focus on innovation[15] Tax and Government Subsidies - The company reported a significant increase in tax payable by 121.69%, reaching ¥13,154,202.38 due to higher VAT, property tax, and land use tax[7] - The company received government subsidies amounting to ¥1,116,830.60, which are closely related to its normal business operations[6] Other Information - The company recorded an asset impairment loss of -¥383,350.04, which is a 116.47% increase compared to -¥177,095.25 in the previous year[7] - The first quarter report was not audited[19] - The report was released by the board of directors on April 27, 2023[20] - The company did not report any significant new product launches or market expansions during this quarter[16] - There were no acquisitions or mergers reported in the current quarter[16]

债券代码：128091 债券简称：新天转债 证券代码：002873 证券简称：新天药业 贵阳新天药业股份有限公司投资者关系活动记录表 编号：2023-005 | | □特定对象调研 □分析师会议 □媒体采访 □√业绩说明会 | | --- | --- | | 投资者关系活 | | | 动类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 | | 参与单位名称 | 通过线上参与公司 年度业绩网上说明会的投资者 2022 | | 及人员姓名 | | | 时间 | 年 月 日 2023 4 12 15:00-17:00 | | 地点 | 深圳证券交易所"互动易"平台、"新天药业投资者关系"微信小程序 | | | 董事长、总经理：董大伦先生 | | 上市公司接待 | 董事、副总经理、董事会秘书：王光平先生 | | 人员姓名 | 财务总监：曾志辉女士 | | | 独立董事：官峰先生 | | | 问题 1、您好，领导，促进公司发展的有利因素很多，那我想咨询一下，公 | | | 司认为哪些方面制约公司业务，谢谢。 | | | 答：第一，企业经营发展优势暨保持稳健可持续增长，已经具备以下几个 | ...

关于举行2022年度业绩网上说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 贵阳新天药业股份有限公司（以下简称"公司"）2022 年年度报告及其摘 要已经第七届董事会第七次会议审议通过。具体内容详见公司指定信息披露媒体 《证券日报》和巨潮资讯网（http://www.cninfo.com.cn）于 2023 年 3 月 28 日发 布的《2022 年年度报告摘要》（公告编号：2023-013），《2022 年年度报告》 （公告编号：2023-012）同日发布于巨潮资讯网（http://www.cninfo.com.cn）。 为便于广大投资者进一步了解公司生产经营情况，公司定于 2023 年 4 月 12 日（星期三）下午 15:00-17:00 在深圳证券交易所"互动易"平台及"新天药业 投资者关系"微信小程序同步举行 2022 年度业绩网上说明会。本次年度业绩说 明会采用网络远程的方式举行，投资者可通过以下两种方式参与互动交流，具体 如下： | 证券代码：002873 | 证券简称：新天药业 | 公告编号：2023-022 | | --- | ...

Financial Performance - The company reported a cash dividend of 1.00 RMB per 10 shares (including tax) to all shareholders, with no bonus shares issued[4]. - The company’s total revenue for the year 2022 was not explicitly stated in the provided content, but the financial report ensures the accuracy and completeness of the financial statements[3]. - The company's operating revenue for 2022 was ¥1,087,673,294.88, representing a 12.15% increase compared to ¥969,844,472.18 in 2021[20]. - The net profit attributable to shareholders for 2022 was ¥116,101,897.84, a 15.40% increase from ¥100,605,308.02 in 2021[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥105,769,379.89, up 12.71% from ¥93,839,366.09 in 2021[20]. - The basic earnings per share for 2022 was ¥0.5007, reflecting a 13.13% increase from ¥0.4426 in 2021[20]. - The total assets at the end of 2022 amounted to ¥1,843,850,779.14, a 20.95% increase from ¥1,524,426,501.68 at the end of 2021[20]. - The net assets attributable to shareholders at the end of 2022 were ¥1,129,201,797.73, which is a 26.81% increase from ¥890,443,409.78 at the end of 2021[20]. - The cash flow from operating activities for 2022 was ¥75,818,174.01, a decrease of 39.00% compared to ¥124,300,304.12 in 2021[20]. - The company received government subsidies amounting to ¥8,234,619.83 in 2022, compared to ¥8,789,898.32 in 2021[27]. Market Position and Strategy - The company plans to expand its market presence and is actively pursuing new product development and technological advancements[4]. - The company is positioned in the traditional Chinese medicine sector, which is experiencing favorable policy support and innovation growth[31]. - The company achieved a market-leading position in the gynecology sector, with its main products reaching over 100 million in market scale[38]. - In the first half of 2022, the company ranked first in sales of gynecological traditional Chinese medicine in public medical institutions, surpassing a 5% market share[39]. - The company plans to optimize its product structure and market distribution, expecting significant growth in business development in the coming years[42]. - The company aims to strengthen its role in public health emergencies and improve the management system for traditional Chinese medicine[36]. - The company is actively expanding its market presence in the field of women's health and reproductive health[44]. - The company has initiated the "Dragon Gate Plan" for market expansion, which is expected to roll out nationwide in 2023[65]. Research and Development - The company is committed to innovation in drug development, emphasizing clinical value and supporting original innovation in pharmaceuticals[34]. - The company has completed clinical phase III trials for three new traditional Chinese medicine products, with 445 varieties of traditional Chinese medicine formula granules and 179 completed national standard filings[47]. - The company holds 30 invention patents, 2 utility model patents, and 13 design patents, with 11 national new drug certificates obtained[48]. - The company has established three R&D platforms, employing 173 technical staff, which accounts for 18.62% of total employees, focusing on traditional Chinese medicine innovation[59]. - The company is enhancing its R&D capabilities and management to improve efficiency and ensure timely product launches[111]. - The company is focusing on brand building, particularly for its OTC brand "He Yan" and aims to establish a strong academic brand among healthcare professionals[112]. Governance and Compliance - The company maintains a strong governance structure, with no regulatory inquiries or compliance issues reported during the year[121]. - The board of directors was restructured, with the addition of two new independent directors to enhance oversight and governance[123]. - The company adheres to strict information disclosure obligations, ensuring that all shareholders receive accurate and timely information[127]. - The company has established a robust independent financial accounting system, allowing for independent financial decision-making and management[136]. - The company has a dedicated internal audit department to oversee significant transactions and ensure compliance with internal control systems[129]. - The company has established a comprehensive governance structure, including a board of directors and various committees to enhance decision-making efficiency[135]. Employee and Talent Management - The company has established a training center to enhance employee skills through a mixed training model, combining online and offline methods[177]. - The company has a dual career development path for employees, focusing on both management and technical skills to support talent retention[177]. - The company has a significant focus on employee performance evaluation and incentive mechanisms to foster a high-efficiency work environment[176]. - The total remuneration for the board of directors, supervisors, and senior management during the reporting period amounted to 759.31 million CNY[163]. - The company has implemented an annual salary system for senior and middle management, along with annual performance evaluations[175]. Financial Management and Investments - The company has committed to invest a total of 45,351.6 million in various projects, with 43,983.07 million already utilized[98]. - The company has not engaged in any significant equity investments during the reporting period[90]. - The company reported a total revenue of 21,351.4 million yuan for the year, an increase from 19,268.1 million yuan in the previous year, representing a growth of approximately 10.8%[103]. - The company plans to enhance its production capacity for traditional Chinese medicine (TCM) formulations, with a revised investment scale of 55.01 million yuan, down from the original 99.58 million yuan[103]. - The company has raised ¥31,702.02 million from its initial public offering, with a net amount of ¥28,969.23 million after deducting issuance costs[96]. Risk Management - The management discussed potential risks and corresponding mitigation strategies in the future outlook section of the report[4]. - The company emphasizes the importance of risk awareness among investors regarding forward-looking statements in the report[4]. - The company is actively monitoring industry policy changes to mitigate risks related to drug pricing and market access[113]. - The company is implementing measures to manage environmental risks associated with production processes, aiming to reduce the proportion of environmental costs in overall expenses[114]. Production and Operations - The company has established a comprehensive production line for various forms of traditional Chinese medicine, including hard capsules, granules, and gels, certified by GMP[41]. - The production process strictly adheres to GMP requirements, with quality supervision at every stage to ensure product compliance[51]. - The company has completed the automation and intelligent upgrades of multiple formulation production lines, with two advanced modern intelligent production lines expected to be completed by June 2023, ensuring a projected capacity demand of 4 billion in value over the next five years[52]. - The company has established long-term stable relationships with suppliers, ensuring quality through comprehensive evaluations and audits[50]. Shareholder Engagement - The company conducted multiple investor relations activities in January 2022, including three research meetings on January 5, 12, and 20, focusing on company introduction and operational conditions[116]. - The company reported a 41.37% investor participation rate in the 2021 Annual General Meeting held on May 9, 2022[137]. - The company has committed to avoiding any competition with its controlling shareholder and has established independent operational and financial practices[132].